Tazemetostat was the first EZH2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and adolescents (≥16 years) with advanced or metastatic epithelioid sarcomas, which are not suitable for surgery or other standard treatments, and for relapsed/refractory follicular lymphoma in adult patients [31]. Here, EZH2 is linked to epithelioid sarcoma.